These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3161481)

  • 61. Cardiovascular effects of ketanserin in conscious rabbits.
    Takata M; Zhang X; Sugimoto T; Ikeda K; Tomoda F; Mikawa M; Iida H; Mizumura Y
    Jpn Heart J; 1986 Jan; 27(1):95-106. PubMed ID: 2941601
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ketanserin and alpha 1-adrenergic antagonism in humans.
    Zabludowski JR; Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S123-5. PubMed ID: 2412032
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cardioprotective effects of carbocromen in awake and anesthetized dogs with amitriptyline poisoning.
    Fiedler VB; Göbel H; Nitz RE
    J Cardiovasc Pharmacol; 1985; 7(4):666-72. PubMed ID: 2410706
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hemodynamic profile of neuropeptide Y in dogs: effect of ganglionic blockade.
    Hashim MA; Harrington WW; Daniels AJ; Tadepalli AS
    Peptides; 1997; 18(2):235-9. PubMed ID: 9149295
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Reflex cardiovascular and respiratory effects of serotonin in conscious and anesthetized dogs.
    Zucker IH; Cornish KG
    Circ Res; 1980 Oct; 47(4):509-15. PubMed ID: 7408129
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hemodynamic and electrocardiographic effects of fluoxetine and its major metabolite, norfluoxetine, in anesthetized dogs.
    Steinberg MI; Smallwood JK; Holland DR; Bymaster FP; Bemis KG
    Toxicol Appl Pharmacol; 1986 Jan; 82(1):70-9. PubMed ID: 3484846
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of 5-hydroxytryptamine in the feline response to intravenous infusion of live E. coli.
    Arvidsson S; Falk A; Haglind E; Haglund U
    Br J Pharmacol; 1983 Jul; 79(3):711-8. PubMed ID: 6360276
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
    Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG
    Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats.
    Pawlak D; Adamkiewicz M; Malyszko J; Takada A; Mysliwiec M; Buczko W
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):266-73. PubMed ID: 9700989
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hypotensive actions of ketanserin in dogs: involvement of a centrally mediated inhibition of sympathetic vascular tone.
    Phillips CA; Mylecharane EJ; Markus JK; Shaw J
    Eur J Pharmacol; 1985 May; 111(3):319-27. PubMed ID: 2862048
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Haemodynamic response to ketanserin in rabbits with Page hypertension: comparison with prazosin.
    Wright CE; Angus JA
    J Hypertens; 1983 Aug; 1(2):183-90. PubMed ID: 6681038
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hemodynamic response to chronic ketanserin treatment in essential hypertension.
    Fagard R; Fiocchi R; Lijnen P; Staessen J; Amery A
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S128-9. PubMed ID: 2412034
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension.
    McGoon MD; Vlietstra RE
    Int J Cardiol; 1987 Mar; 14(3):303-9. PubMed ID: 3557709
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Chronic serotonergic blockade with ketanserin in the spontaneously hypertensive rat.
    Pettersson A; Gradin K; Hedner T; Henning M; Persson B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S112-3. PubMed ID: 2412027
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ketanserin, a serotonin antagonist. Administration in patients with acute respiratory failure.
    Vincent JL; Degaute JP; Domb M; Simon P; Berre J; Vandesteene A
    Chest; 1984 Apr; 85(4):510-3. PubMed ID: 6705581
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serotonin-induced renin release in the dog kidney.
    Takahashi T; Hisa H; Satoh S
    Eur J Pharmacol; 1991 Feb; 193(3):315-20. PubMed ID: 1905236
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of ketanserin, a 5-HT2-receptor antagonist, on the blood flow response to temperature changes in the diabetic foot.
    Schneider SH; Tendler M; Apelian A; Jageneau AH; Khachadurian AK
    J Clin Pharmacol; 1985 Sep; 25(6):413-7. PubMed ID: 2932476
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acute effects of ketanserin on left ventricular function, metabolism and coronary blood flow.
    Walker JM; Wilmshurst PT; Juul SM; Coltart DJ
    Br J Clin Pharmacol; 1984 Mar; 17(3):301-7. PubMed ID: 6712862
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacological manipulation of cardiovascular responses to lower body negative pressure.
    Perko G; Schmidt JF; Warberg J; Secher NH
    Eur J Appl Physiol Occup Physiol; 1996; 73(5):459-64. PubMed ID: 8803507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.